News stories about Organovo (NASDAQ:ONVO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Organovo earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 47.9361017650137 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Here’s What to Focus on – Nasdaq Journal (nasdaqjournal.com)
- Historical Performances are Key to Consider – Organovo Holdings Inc (NASDAQ: ONVO) – Stocks Pen (stockspen.com)
- Zacks: Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.07 Earnings Per Share (americanbankingnews.com)
- Analysts recommended an average rating score of 1.70 for Organovo Holdings, Inc. (ONVO) – Wall Street Morning (wallstreetmorning.com)
- Buyers and Sellers Alert – Organovo Holdings, Inc. (ONVO) – Nasdaq Fortune (press release) (nasdaqfortune.com)
Several brokerages have weighed in on ONVO. Zacks Investment Research cut Organovo from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. BTIG Research reaffirmed a “buy” rating and set a $3.00 target price on shares of Organovo in a research report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Organovo has a consensus rating of “Hold” and an average target price of $3.40.
Organovo (NASDAQ:ONVO) last announced its earnings results on Thursday, February 8th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The firm had revenue of $1.15 million during the quarter, compared to analyst estimates of $1.25 million. During the same period last year, the firm posted ($0.09) EPS. The business’s revenue was up .0% compared to the same quarter last year. sell-side analysts predict that Organovo will post -0.33 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Organovo (NASDAQ:ONVO) Receiving Somewhat Positive Press Coverage, Accern Reports” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/03/14/organovo-onvo-earns-daily-media-sentiment-rating-of-0-19/1926330.html.
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.